California State Teachers Retirement System Buys 23,304 Shares of Edwards Lifesciences Corporation $EW

California State Teachers Retirement System grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 2.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 895,004 shares of the medical research company's stock after purchasing an additional 23,304 shares during the quarter. California State Teachers Retirement System owned about 0.16% of Edwards Lifesciences worth $80,962,062 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $1,274,082,000. Norges Bank acquired a new position in Edwards Lifesciences in the fourth quarter worth about $803,686,000. Bank of America Corp DE bought a new position in shares of Edwards Lifesciences in the second quarter worth $605,397,000. Finally, Deutsche Bank AG purchased a new stake in Edwards Lifesciences in the 2nd quarter worth about $516,552,000. Institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the company's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president directly owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction on Friday, September 11th. The stock was sold at an average price of $87.51, for a total value of $54,168.69. Following the sale, the vice president owned 40,034 shares of the company's stock, valued at approximately $3,503,375.34. The trade was a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,664 shares of company stock worth $511,918 in the last ninety days. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

EW stock traded up $0.14 during midday trading on Tuesday, reaching $85.66. 1,500,635 shares of the stock were exchanged, compared to its average volume of 4,577,705. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a fifty day moving average price of $88.97 and a 200 day moving average price of $85.84. The stock has a market capitalization of $49.33 billion, a PE ratio of 49.22, a P/E/G ratio of 2.21 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm's revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on EW. Wall Street Zen raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Saturday. Citigroup upped their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Mizuho lifted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. Piper Sandler reissued an "overweight" rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Finally, Truist Financial increased their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research report on Thursday, July 16th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.